title: Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model.
abstract: To evaluate efficacy and MRI findings after intravenous bevacizumab and/or carboplatin in a human glioma animal model, we randomized male nude rats with intracerebral UW28 human glioma xenografts to four groups: (1) controls (n = 9), (2) bevacizumab 10 mg/kg (n = 6), (3) carboplatin 200 mg/m(2) (n = 6), and (4) bevacizumab + carboplatin (n = 6). MRI was performed on the day of treatment (day 7-10) and 1 week later, and rats were followed for survival. Dynamic MRI was done in three controls and three rats treated with bevacizumab with or without carboplatin before and 24 h after treatment. Median overall survival (OS) was as follows: group 1, 16 days; group 2, 23 days; group 3, 22 days; group 4, 36 days. OS was significantly longer in group 4 than in group 1 (p = 0.0011), group 2 (p = 0.0014), and group 3 (p = 0.0015), and rats had significantly larger tumors. No objective tumor responses were observed on MR images at 1 week after treatment; however, after bevacizumab, dynamic MRI showed reduced gadolinium enhancement intensity and increased time to peak, consistent with decreased vascular permeability. Carboplatin + bevacizumab is effective and superior over bevacizumab or carboplatin monotherapy in this animal model. Increased survival concomitant with increased asymptomatic tumor volume is suggestive that vascular targeting with reduced peritumoral edema and mass effect contributes to the efficacy of bevacizumab. The promising survival data warrant future clinical trials using bevacizumab + carboplatin.
authors.affiliation: Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin Medizinische Klinik m. S. Hämatologie und Onkologie, Berlin, Germany.
authors.forename: Kristoph
authors.initials: K
authors.lastname: Jahnke
authors.forename: Leslie L
authors.initials: LL
authors.lastname: Muldoon
authors.forename: Csanad G
authors.initials: CG
authors.lastname: Varallyay
authors.forename: Seth J
authors.initials: SJ
authors.lastname: Lewin
authors.forename: Dale F
authors.initials: DF
authors.lastname: Kraemer
authors.forename: Edward A
authors.initials: EA
authors.lastname: Neuwelt
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016190:Carboplatin / Q000008:administration & dosage; D004195:Disease Models, Animal; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D051381:Rats; D011923:Rats, Nude; D015996:Survival Rate; D047368:Tumor Burden
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016190:Carboplatin
references.citation: Clin Cancer Res. 2007 Feb 15;13(4):1253-9
references.pmid: 17317837
references.citation: Cancer Cell. 2004 Dec;6(6):553-63
references.pmid: 15607960
references.citation: Cancer Chemother Pharmacol. 1994;33(6):477-83
references.pmid: 8137457
references.citation: Cancer Cell. 2007 Jan;11(1):83-95
references.pmid: 17222792
references.citation: Neuro Oncol. 2004 Jan;6(1):21-7
references.pmid: 14769136
references.citation: Cancer Res. 2006 Aug 15;66(16):7843-8
references.pmid: 16912155
references.citation: Cancer Res. 2004 Jun 1;64(11):3731-6
references.pmid: 15172975
references.citation: J Clin Oncol. 2003 Apr 15;21(8):1485-91
references.pmid: 12697871
references.citation: J Neurooncol. 2002 Jan;56(1):79-86
references.pmid: 11949830
references.citation: Neurology. 2006 Apr 25;66(8):1258-60
references.pmid: 16636248
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4705-6
references.pmid: 17947716
references.citation: Cancer. 2003 May 1;97(9 Suppl):2381-6
references.pmid: 12712460
references.citation: J Magn Reson Imaging. 2004 Nov;20(5):865-73
references.pmid: 15503324
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: J Clin Oncol. 1999 May;17(5):1516-25
references.pmid: 10334539
references.citation: Magn Reson Imaging. 1999 Nov;17(9):1297-305
references.pmid: 10576715
references.citation: J Clin Oncol. 1991 May;9(5):860-4
references.pmid: 1849986
references.citation: J Neurooncol. 2001 Jan;51(2):133-41
references.pmid: 11386410
references.citation: J Neurooncol. 2002 Jan;56(2):183-8
references.pmid: 11995820
references.citation: J Neurooncol. 1991 Apr;10(2):139-44
references.pmid: 1654401
references.citation: Clin Adv Hematol Oncol. 2006 Jan;4(1):suppl 1-10; quz 11-2
references.pmid: 16562372
references.citation: Neuro Oncol. 2006 Apr;8(2):189-93
references.pmid: 16533878
references.citation: Technol Cancer Res Treat. 2005 Jun;4(3):245-9
references.pmid: 15896079
references.citation: Magn Reson Med. 2003 May;49(5):848-55
references.pmid: 12704767
references.citation: Anticancer Drugs. 2002 Feb;13(2):163-7
references.pmid: 11901309
references.citation: J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):481-6
references.pmid: 10480340
references.citation: J Pharmacol Exp Ther. 2004 May;309(2):594-9
references.pmid: 14752063
references.citation: Anticancer Res. 1998 Nov-Dec;18(6B):4693-7
references.pmid: 9891542
references.citation: J Neurooncol. 1994;19(1):69-74
references.pmid: 7815106
references.citation: Neurology. 2008 Mar 4;70(10):779-87
references.pmid: 18316689
references.citation: Clin Cancer Res. 2005 Feb 15;11(4):1669-74
references.pmid: 15746072
references.citation: Nature. 2000 Sep 14;407(6801):249-57
references.pmid: 11001068
references.citation: Br J Cancer. 2000 Sep;83(5):588-93
references.pmid: 10944597